Cost Implications for Novel Therapies and Strategies in the Treatment of NSCLC: Perspectives and Clinical Updates from ASCO 2011

42 I VALUE-BASED CANCER CARE I August 2011 VOL. 2 I NO. 5 Presentations from the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) provide an ideal forum for payers grappling with reimbursement issues and benefit design for patients with non–smallcell lung cancer (NSCLC) and for pharmacists who must understand emerging treatments. This article summarizes key clinical studies and expert discussions that describe current trends in the management of this increasingly complex and mutation-driven tumor and their cost implications. The shifting landscape in NSCLC management highlights the need to align providers’ and payers’ strategies to enhance high-quality, value-based patient care.